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Abstract
Background: Although the majority of small in-frame insertions/deletions (indels) has no or little effect on protein
function, a subset of these changes has been causally associated with genetic disorders. Notably, the molecular
mechanisms and frequency by which they give rise to disease phenotypes remain largely unknown.
The aim of this study is to provide insights into the role of in-frame indels (≤21 nucleotides) in two genetically
heterogeneous eye disorders.
Results: One hundred eighty-one probands with childhood cataracts and 486 probands with retinal dystrophy
underwent multigene panel testing in a clinical diagnostic laboratory. In-frame indels were collected and evaluated
both clinically and in silico. Variants that could be modeled in the context of protein structure were identified and
analysed using integrative structural modeling. Overall, 55 small in-frame indels were detected in 112 of 667 probands
(16.8 %); 17 of these changes were novel to this study and 18 variants were reported clinically. A reliable model of the
corresponding protein sequence could be generated for 8 variants. Structural modeling indicated a diverse range of
molecular mechanisms of disease including disruption of secondary and tertiary protein structure and alteration of
protein-DNA binding sites.
Conclusions: In childhood cataract and retinal dystrophy subjects, one small in-frame indel is clinically reported in
every ~37 individuals tested. The clinical utility of computational tools evaluating these changes increases when the full
complexity of the involved molecular mechanisms is embraced.
Keywords: Inherited eye disease, Retinal dystrophy, Childhood cataract, In-frame insertions/deletions, Homology
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Background
Small insertions/deletions (indels) are the second most
abundant form of human genetic variation after single
nucleotide variants (SNVs) [1]. These DNA changes
can influence gene products through multiple mecha-
nisms, including altering amino acid sequence and
affecting gene expression [2]. A number of computational
tools that functionally annotate indels are available includ-
ing SIFT-indel [3], PROVEAN [4], DDG-in [5], CADD
[6], PriVar [7], PinPor [2], HMMvar [8], KD4i [9], and
VEST-indel [10]. Although some of these tools are re-
ported to achieve relatively high sensitivity and specificity
values [10], predicting the effect of protein-coding (frame-
shifting, in-frame) and non-protein-coding indels in the
clinical setting remains a formidable challenge [11].
Inherited eye disorders such as childhood cataracts
(CC) and retinal dystrophies (RD) are a major cause of
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blindness among children and working-age adults [12,
13]. Over the past decades, exciting progress has been
made in elucidating the genetic basis of these disorders.
Hundreds of disease-causing genes have been identified
leading to the development of diagnostic tests that are
now regularly used in clinical practice [14, 15]. The pre-
ferred testing method at present is panel-based genetic
diagnostic testing [16], although whole genome sequen-
cing is increasingly being used in the clinical domain
[17]. For these tests to have the greatest medical impact,
it is necessary to be able to pinpoint the disease-causing
variant(s) among the considerable background of de-
tected rare changes that might be potentially functional
but not actually responsible for the phenotype under
investigation [18]. Guidelines for assigning clinical sig-
nificance to sequence variants have been developed [19]
and it is clear that, among protein-coding changes, in-
frame indels present a unique challenge.
When the phenotypic relevance of a protein-coding
variant is investigated, knowledge of the structure and
biochemistry of the associated protein can be very
useful. Unfortunately, due to limitations of mainstream
structural biology techniques (X-ray crystallography
[XRC], nuclear magnetic resonance [NMR], 3D elec-
tron microscopy [3DEM]), experimentally determined
structures are available for only a small proportion of
proteins [20]. Recently, computational methods have
been used to generate reliable structural models based
on complementary experimental data and theoretic
information [21]. Such integrative modeling approaches
can be utilised to evaluate protein-coding variants in
silico, on the basis of 3D structure and molecular
dynamics [22].
In this study, a variety of methods including integrative
modeling, are used to gain insights into the role of in-
frame indels in two genetically heterogeneous Mendelian
disorders, CC and RD. Clinical genetic data (multigene
panel testing) from 667 individuals are presented and 17
previously unreported in-frame indels are described.
Methods
Clinical samples
Unrelated subjects with inherited eye disorders were
retrospectively ascertained through the database of the
Manchester Regional Genetic Laboratory Service,
Manchester, UK. Referrals were received between Oc-
tober 2013 and December 2015 from multiple clinical
institutions in the UK and around the world, although
a significant proportion of samples came from the
North West of England. After obtaining informed con-
sent from the affected individual/family, the referring
physician requested a multigene panel test. The reason
for referral was included in the clinical data completed
by the referring medical specialist. Extensive
phenotypic information was available for subjects re-
ferred from the Central Manchester University Hospi-
tals, Manchester, UK. Ethics committee approval was
obtained from the North West Research Ethics Commit-
tee (11/NW/0421 and 15/YH/0365) and all investigations
were conducted in accordance to the tenets of the Declar-
ation of Helsinki.
Genetic and bioinformatic analysis
Testing and analysis were performed at the Manchester
Regional Genetic Laboratory Service, a United Kingdom
Accreditation Service (UKAS) - Clinical Pathology Accre-
dited (CPA) medical laboratory (CPA number 4015). DNA
samples were processed using Agilent SureSelect (Agilent
Technologies, Santa, Clara, CA, USA) target enrichment
kits designed to capture all exons and 5 base pairs (bp) of
the flanking intronic sequence of either
(i) 114 genes associated with CC and/or anterior
segment developmental anomalies [14] or
(ii)176 genes associated with RD.
The genes were selected after interrogating publically
available databases (http://cat-map.wustl.edu and http://
sph.uth.edu/retnet/) and the literature. A list of all the
tested transcripts/genes can be found in Additional file
1: Table S1.
After enrichment, the samples were sequenced on an
Illumina HiSeq 2500 system (Illumina Inc, San Diego,
CA, USA; 100 bp paired-end reads) according to the
manufacturer’s protocols. Sequence reads were subse-
quently demultiplexed using CASAVA v1.8.2 (Illumina
Inc, San Diego, CA, USA) and aligned to the hg19
reference genome using the Burrows Wheeler Aligner
(BWA-short v0.6.2) [23]. Duplicate reads were removed
using Samtools before base quality score recalibration
and indel realignment using the Genome Analysis Tool
Kit (GATK-lite v2.0.39) [24]. The UnifiedGenotyper
within GATK was used for SNV and indel discovery [25];
indels supported by <0.1 of the reads were discarded and
the quality metrics for keeping SNVs included read depth
≥50x and mean quality value (MQV) ≥45.
Previous studies have shown that the number of indels
called has a significant positive correlation with the
coverage depth [26–28]. Therefore, only samples in which
≥99.5 % of the target region was covered to a minimum
depth of 50x were included.
Variant annotation and clinical variant interpretation
was performed as previously described [14, 15].
Briefly, the Ensembl Variant Effect Predictor (VEP)
was used to assign functional consequences to SNVs
and indels. Variants with allele frequency >1 % in in
large publically available datasets (National Heart,
Lung, and Blood Institute Exome Sequencing Project
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Exome Variant Server ESP6500 and dbSNP v135) were
deemed benign and were not analysed further. The
remaining changes were assigned a pathogenicity clas-
sification score according to previously described
methods [14, 15, 19]. Variants that were suspected to
be pathogenic or relevant were included in a clinical
report (“clinically reported’), while all other rare
changes were included in a technical report. Certain
flagged cases were reviewed in a monthly multidiscip-
linary team (MDT) meeting who discussed in detail
the family history, phenotypic presentation and rele-
vant pathogenicity of the identified variants [15]; the
decision to include a change in the clinical or tech-
nical report was not altered by the MDT. All clinic-
ally reported SNVs and indels, and all indels that
were novel to this study (i.e. not previously described
in Ensembl VEP v83) were confirmed by Sanger se-
quencing; no false positives were detected. On a few
occasions, samples from family members were also
analyzed with Sanger sequencing.
Small insertion/deletion analysis
There is no consensus in the literature about the size
range of a ‘small indel’ and, here, we define it as a gain
or loss of ≤21 nucleotides at a single locus [2]. There are
two reasons for this choice. First, when the Illumina
short-read sequencing platform is used, available bio-
informatics tools can only detect relatively small indels
[28]. Importantly, the sensitivity of such tools is greatly
reduced for variants >21 bp [29]. Second, there is evi-
dence to suggest that indels of length ≤21 bp make up
the vast majority of all indel events, especially exonic
ones [1, 30, 31].
Small in-frame indels were collected and manually
checked for redundancy with respect to variants already
in Ensembl Release 83 (accessed 03 Mar 2016). Further-
more, changes within 2 bp from intron-exon boundaries
were sought after. Indels were then classified based on
their primary sequence context into homopolymer runs
(HR; if the variant was within a run of six or more iden-
tical bases) and tandem repeats (TR; if the variant was
within a segment of at least two repeated sequences)
[30]. In silico analysis using the SIFT-indel [3], PRO-
VEAN [4] and DDG-in [5] computational tools was
subsequently performed (all accessed 03 Mar 2016).
These three tools were selected as they were freely avail-
able at the time of the study design, they have been shown
to have high accuracy (>0.80), and they are among the
most widely used methods in the field [10].
Integrative protein structure modeling was attempted
for all proteins found to harbour small in-frame indels.
Reference amino acid sequences (obtained from Uni-
Prot) were used to ‘search by sequence’ in the RCSB
Protein Data Bank (PDB; accessed 03 Mar 2016) [32];
the BLAST method and an E-value cutoff of 10−3 were
used.
Manual inspection of the generated alignments was
subsequently performed. A prerequisite for reliable inte-
grative modeling is amino acid sequence similarity be-
tween the experimentally determined structural model
and the input protein. For the purposes of the present
study, the area around the mutated locus is of particular
importance. Therefore, only cases with >5/11 sequence
identity in the part of the alignment that included the
variant locus and 5 flanking residues on either side were
selected. We note that there is no consensus on what
constitutes sufficient sequence similarity for reliable in-
tegrative modeling, and that setting this threshold was
informed by the prior experience of our group. The
RCSB PDB entry that matched the input protein most
closely was then chosen and Clustal Omega v1.2.1 [33]
was used to align the ATOM sequence of the template
PDB file (i.e., the one describing homologous proteins of
known structure) to the input protein sequence. Integra-
tive models were subsequently generated using Modeller
9.16 [34]: ten models were built for each case and the
one with the lowest Discrete Optimized Protein Energy
score was chosen. The KiNG 2.21 [35] tool was used to
visualize the generated 3D protein models.
Results
Genetic findings and clinical evaluation
Overall 181 probands with CC and/or anterior segment
developmental anomalies (“CC group”) and 486 pro-
bands with RD (“RD group”) met the inclusion criteria
for this study. In the CC group, 114 genes were analysed
per case and a total of 11 small in-frame indels were
detected in 12/181 study subjects. In the RD group, 176
genes were analysed per case and a total of 44 small in-
frame indels were detected in 99/486 study subjects.
Only one of these indels was detected in homozygous
state, CDHR1 c.690_692del. Notably, 17/55 (30.9 %)
changes were novel to this study while 13/55 (23.6 %)
variants were detected on multiple samples (range 2–21),
and 35/55 (63.6 %) were found in a TR context. The mean
and median number of affected amino acid residues was
2.2 and 1.5 respectively (range 1–7 amino acids as per def-
inition of small indel used in this study). A detailed list of
the identified variants can be found in Additional file 1:
Table S2.
In terms of clinical evaluation, 5/11 changes from the
CC group and 13/44 changes from the RD group were
included in clinical reports; all remaining variants were
included in technical reports. Genes in which clinically
reported in-frame changes were identified include BFSP2,
CRYBA1, CRYBA4, CRYGC, PITX2, ABCA4, ADGRA3,
CDHR1, CHM, CRB1, FLVCR1, INPP5E, NYX, PRPH2,
RP2, RPE65 and RS1; a list of previously reported disease-
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associated small in-frame indels in these genes is shown in
Additional file 1: Table S3. The predictions from all
three computational tools used in this study (SIFT-
indel, PROVEAN and DDG-in) were in agreement in 8/
11 CC group variants and in 26/44 RD group variants.
However, these predictions were not always in keeping
with the conclusion in the clinical report. A notable ex-
ample is the ABCA4 c.3840_3845del variant which was
predicted neutral by all three tools but was reported to
probably account for the clinical presentation in a 7-year-
old study subject. This proband harbors another ABCA4
change, c.1928G > T and has bilateral macular atrophy
and yellow-white retinal lesions (flecks), a phenotype sug-
gestive of ABCA4-retinopathy [36]. A second example is
the FSCN2 c.1071_1073del variant which was predicted to
be damaging by all three in silico tools but was not consid-
ered likely to account for the clinical presentation in the
affected proband. To date, the only reported link between
FSCN2 and retinal disease is a single bp deletion
(rs376633374) that was identified in Japanese subjects
with either retinitis pigmentosa [37] or macular dystrophy
[38]. However, this variant did not segregate with retinal
disease in Chinese families [39] and is unlikely to cause
disease in a Mendelian fashion. Importantly, the pro-
band, a 11-year-old subject with undetectable electrore-
tinograms and an early-onset RD, also harbors a
homozygous GUCY2D c.2285delG change. Biallelic
GUCY2D changes are a common cause of early-onset
RD and the c.2285delG change has been previously de-
scribed in a 2-year-old affected individual [40]. Given
the phenotype and the genetic findings it is much more
likely that the condition is caused by recessive GUCY2D
variants compared to dominant FSCN2 variants.
When integrative structural modeling was attempted,
reliable models of the relevant protein sequences could
be generated for 8/55 small in-frame indels (14.5 %; 5/11
in the CC group, 3/44 in the RD group) (Table 1).
Integrative structural modeling in childhood cataract cases
In the majority of cases, simply highlighting the position
of the indel on the protein structure gave a clear indica-
tion of its likely phenotypic effect. For both CRYBA1
c.272_274del and CRYBA4 c.136_156del variants the
deleted residues are in β-sheets. The CRYBA1 change is
a single residue deletion (Gly91) in an edge strand
(Fig. 1a), whereas the CRYBA4 change is a larger dele-
tion (Ser46_Gly52del) in a central strand (Fig. 1b). In
general, β-sheet structures are highly constrained due
to their hydrogen bond network [41] and so amino acid
insertions and deletions are likely to be deleterious
[42]. In conclusion, the CRYBA1 and CRYBA4 variants
are likely to destabilise the corresponding proteins,
leading to misfolding and aggregation. By contrast, the
effect of the CRYGC c.61_63del variant is less clear as it
removes an amino-acid (Thr21del) from a loop between
two β-strands.
In the case of BFSP2 c.697_699del, the deleted residue
(Glu233) is in the main α-helical region. In the wild-
type, a long, continuous hydrophobic interface is formed
between the protein chains (Fig. 1c, left hand-side image).
Since there are 3.6 residues per turn in every α-helix, dele-
tion of a single residue shifts the position of these hydro-
phobic residues from the internal interface to the surface
of the protein (Fig. 1c, right hand-side image). The
deletion is therefore likely to have two effects: firstly, the
cognate interaction between the protein chains will be dis-
rupted and secondly hydrophobic residues that are found
on the surface of the protein in the mutant form will be
able to form a wide array of non-cognate interactions,
with the potential to form large aggregates.
For PITX2 c.429_431del, the deleted residue (Arg144)
is in a surface loop, which, in general, is a structural
context that is able to accommodate changes without
substantially affecting protein folding. However, in the
wild-type protein, Arg144 appears to make direct con-
tact with the phosphate backbone of DNA forming a
salt bridge (Fig. 1d). We therefore hypothesize that
deletion of this residue would destabilise the protein-
DNA interaction.
Integrative structural modeling in retinal dystrophy cases
Indels in RD-associated genes offer useful contrasting
examples. In RP2 c.260_268del the deleted residues
(Thr87_Cys89) are found in a β-prism domain (Fig. 2a).
Such an extended set of β-sheets is formed from coopera-
tive sets of hydrogen bonds, and so any deletion is likely
to be deleterious. By contrast, FSCN2 c.1071_1073del,
leads to the deletion of Lys357 which is in a surface loop,
away from known functional or interaction sites. This
change is therefore unlikely to significantly disrupt protein
structure or function. As discussed above, this deletion is
predicted by SIFT-indel, PROVEAN and DDG-in to be
deleterious, although it is unlikely to account for the
clinical presentation. Therefore, in this case, structural
analysis correlates more closely with clinical evaluation
than sequence-based in silico tools.
The RPE65 c.1443_1445del change is more challenging
to interpret. A negatively charged amino-acid (Glu481del)
is removed resulting in loss of packing interactions that
might contribute to the overall stability of the folded
protein. However, the deletion appears to be away from
catalytic/binding sites of the RPE65 enzyme, and com-
menting on variant pathogenicity on the basis of structural
modeling would be highly speculative.
Discussion
In this study we have investigated the role of small
(≤21 bp) in-frame indels in two inherited eye disorders
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and have shown that integrative structural modeling can
help interpret some of these changes. Known disease-
associated genes were screened in 181 probands with
CC and/or anterior segment developmental anomalies,
and in 486 probands with RD; one small in-frame indel
was clinically reported in 2.8 % (5/181) in 2.7 % (13/486)
of cases respectively.
Although current high-throughput sequencing tech-
nologies provide unprecedented opportunities to detect
genetic variation, it is still not possible to elucidate the
molecular pathology in a significant proportion of cases
with Mendelian disorders [43]. It has been previously
shown that a genetic diagnosis cannot be identified in
in 1 in 3 CC cases [44] and in 1 in 2 RD cases [16]. A
combination of analytical/technical and biological fac-
tors are likely to contribute to this, including incom-
plete testing or knowledge of genes associated with
these disorders [43]. One key factor is the inability of
high-throughput sequencing to consistently and reliably
detect indels [28]. There are two main reasons for this.
First, most indels are associated with polymerase slip-
page and are located in difficult-to-sequence repetitive
regions [30]. In the present study, we have not analysed
4 extremely repetitive exons (such as RPGR ORF15, see
Additional file 1: Table S1) and we would therefore
expect the true number of indel events to be higher.
Second, numerous analytical/technical factors can affect
indel detection accuracy including indel size, read cover-
age, read length and software tool options [28]. To
minimize bias, we focused on small indels (≤21 bp), we
analysed a high coverage subset (samples in which
≥99.5 % of target sequence had ≥50x coverage), and we
employed the widely used Illumina chemistry (100 bp
paired-end reads). Although there are bioinformatic
pipelines that outperform the one utilized in this study
[26–29, 45], at present, there is no gold standard method.
It is noteworthy that the setting of this study is a clinical
diagnostic laboratory and our findings reflect the current
real-world diagnostic context.
To date, over 4000 disease-causing in-frame indels have
been reported, corresponding to 2.2 % of all mutations
(Human Gene Mutation Database, HGMD Professional
release 2015.4). Recently, the 1000 Genomes Project
Consortium reported that 1.4 % of detected exonic vari-
ants were indels [1] and it is expected that at least half of
these changes will be in-frame [31]. Notably, functional
and population annotations for these in-frame indels are
becoming increasing available [1, 10]. In this study, three
computational tools were used and their annotations were
found to be in agreement for 61.8 % (34/55) of variants.
However, the results were probably erroneous for at least
two of these variants (ABCA4 c.3840_3845del and the
FSCN2 c.1071_1073del). It can be speculated that the high
degree of correlation between predictions (including the
incorrect ones) was due to the fact that all three predictive
models evaluated similar sets of variant properties (e.g.
evolutionary conservation scores or regulatory-type anno-
tations). We hypothesized that for the clinical utility to be
maximised, not only the prediction but also the reasons
for the prediction (e.g. disruption of a binding site or a β-
sheet etc.) should be available to the clinician. Protein
structure was therefore used as an endophenotype
(defined by Karchin [11] as ‘measurable component
unseen by the unaided eye along the pathway between
disease and distal genotype’). Importantly only 1 in 7
in-frame indels were found within regions that could be
reliably modeled. This mostly reflects the fact that integra-
tive models often represent only fractions of the full-
Table 1 Small in-frame insertions/deletions for which reliable structural models could be generated













tools for this change?
FSCN2 c.1071_1073del p.(Lys357del) human FSCN1 (pdb 1DFC) unlikely unlikely yes [D/D/D]
RP2 c.260_268del p.(Thr87_Cys89del) human RP2 (pdb 2BX6) probably possibly yes [D/D/D]
RPE65 c.1443_1445del p.(Glu481del) cow RPE65 (pdb 3FSN) unclear probably yes [D/D/D]
BFSP2 c.697_699del p.(Glu233del) human vimentin (pdb 3UF1) probably probably yes [D/D/D]
CRYBA1 c.272_274del p.(Gly91del) human CRYBA4 (pdb 3LWK) probably probably yes [D/D/D]
CRYBA4 c.136_156del p.(Ser46_Gly52del) human CRYBA4 (pdb 3LWK) probably probably yes [D/D/D]
CRYGC c.61_63del p.(Thr21del) human CRYGB (pdb 2JDF) unclear probably yes [D/D/D]
PITX2 c.429_431del p.(Arg144del) human PITX2 (pdb 2LKX) probably probably no [N/D/D]
Assuming the clinical report is the standard and after removing the case where the variant possibly accounted for the clinical presentation (RP2 p. (Thr87_Cys89del)), the
test accuracy was found to be 0.86 for structural modeling, SIFT-indel and PROVEAN, and 0.71 for DDIG-in. SIFT-indel and PROVEAN had the highest sensitivity (1.00)
while structural modeling had the highest specificity (0.75)
[D/D/D] suggests that an in-frame indel was predicted to be disease-associated by DDIG-in, damaging by SIFT-indel and deleterious by PROVEAN; [N/D/D] suggests
that it was predicted to be neutral by DDG-in, damaging by SIFT-indel and deleterious by PROVEAN
For more details on transcripts, RCSB PDB entries, and in silico analysis please see text and Additional file 1: Table S2
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length of a protein [20]. Nevertheless, as new structures
become available and new techniques are developed, the
applicability and utility of the discussed methods is ex-
pected to grow.
A variety of properties can be evaluated to infer the im-
pact of an amino acid sequence change on in vivo protein
activity. Parameters assessed here and in previous studies
include effect on protein folding/stability [46] and conse-
quences on interaction interfaces [22]. Highly accurate
protein structures are required for these types of analyses.
To obtain such structures, we utilized a popular compara-
tive modeling tool (Modeller 9.16 [34]). Notably, a range
of similar tools has been described and objective testing/
evaluation of these methods is regularly performed (see
http://www.predictioncenter.org/). Although the pipeline
and parameters used in this report have been carefully
chosen, the current state of the art method remains to be
established.
Structural analysis of mutant proteins in this study sug-
gested that the abnormal phenotype can arise through diverse
molecular mechanisms. These include alterations in the DNA
interaction site of transcription factors (PITX2 c.429_431del),
and disruption of secondary structural elements in crystallins
(CRYBA1 c.272_274del, CRYBA4 c.136_156del), cytoskeletal
constituents (BFSP2 c.697_699del) and GTPase-activating
proteins (RP2 c.260_268del). This wide range of effects
could only be rationalized with a combination of (i) care-
ful clinical characterization, (ii) knowledge of the molecu-
lar and cellular function of the proteins in question, and
(iii) modeling of the likely effects of indels in the context
of protein structure and protein interactions. There is an
acute need for computational tools that are able to
Fig. 1 Integrative protein structure modeling for four variants identified in individuals with childhood cataracts. Affected amino acids are
highlighted in red. a, b Models of the CRYBA1 c.272_274del, p. (Gly91del) (a) and CRYBA4 c.136_156del, p. (Ser46_Gly52del) (b) variants. The
CRYBA1 and CRYBA4 proteins exhibit significant sequence similarity and the template with pdb code 3LWK (human β-crystallin A4) was used on
both occasions. The main chain backbone atoms (white/grey lines) and the hydrogen bond network (brown lines) of the affected protein regions
are shown. Both sequence alterations involve deleting residues located in β-sheets. c Homology model of the BFSP2 c.697_699del, p. (Glu233del)
variant. BFSP2 forms parallel coiled-coil dimers that interact with one another in the form of a symmetrical anti-parallel dimer. The main chain
backbone atoms (white/yellow lines) and the side chains that comprise the interaction interface (green) of the affected protein region are shown.
The wild-type protein is presented on the left hand-side image. Notably, the affected amino acid is located in an α-helical region (highlighted in
red). The right hand-side image shows a model of the mutant protein; the deletion shifts the position of the interacting side chains resulting in
disruption of the dimer structure and exposure of the hydrophobic interface residues to the protein surface. d Model of the PITX2 c.429_431del,
p. (Arg144del) variant. The main chain backbone atoms of the protein (white/grey lines) complexed with an interacting DNA double helix (brown
chain) are shown. The mutated residue (highlighted in red) makes direct contact with the phosphate backbone of DNA, forming a salt bridge
Sergouniotis et al. Orphanet Journal of Rare Diseases  (2016) 11:125 Page 6 of 8
estimate the relative pathogenicity of sequence variants of
all types, including indels. Our findings suggest that if
such tools are to be effective, they must be able to model
the full complexity of molecular mechanisms by which
pathogenicity arises.
Conclusions
Systematic evaluation of the role of small in-frame
indels in CC and RD revealed a clinically reported vari-
ant in every ~37 individuals tested for each group. Inte-
grative structural modeling can be used to improve the
diagnostic value of genetic testing in inherited eye
disorders. The strategies presented have the potential
to allow disease risk assessment at the atomic level, to
facilitate study of multiple variant interactions (epistasis)
and to guide knowledge-based interventions.
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multigene panel tests for retinal dystrophy and childhood cataracts.
Table S2. Clinical and in silico evaluation of small (≤21 nucleotides) in-
frame insertions/deletions identified by panel-based genetic diagnostic
testing in 486 probands with retinal dystrophy and 181 probands with
childhood cataract. Table S3. Previously reported disease-associated
small in-frame insertions/deletions in genes found to have clinically
reported variants in the present study. (PDF 241 kb)
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